BMY's existing $2B cost-savings program and discounted forward P/E of ~10 make it an attractive AZN acquisition target, Holz argues. Eli Lilly's $1 trillion market cap dwarfs all pharma rivals, ...
It’s the most versatile all-in-one photo organizer, editor and effects tool money can buy, and it’s also one of the cheapest, ...